Clinical Trials on Constipation Predominant Irritable Bowel Syndrome in Australia

Total 22 results

AstraZeneca
Ironwood Pharmaceuticals, Inc.

Completed

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (D5630C00001)

Irritable Bowel Syndrome With Constipation (IBS-C)

United States, Australia, China, New Zealand, Canada
University of Vienna

Completed

Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome (MicFFGAH2013)

Irritable Bowel Disease

Austria
GlaxoSmithKline

Completed

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

Germany, Australia, France
St Vincent's Hospital Melbourne

Completed

The Multi-disciplinary Treatment of Functional Gut Disorders Study (MANTRA)

Functional Dyspepsia | Irritable Bowel Syndrome | Constipation - Functional | Faecal Incontinence | Functional Abdominal Pain Syndrome | Other Rome IV Functional Gastrointestinal Disorders

Australia
Glock Health, Science and Research GmbH

Unknown

G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome With Diarrhea (IBS-D)

Austria
GlaxoSmithKline

Completed

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

Irritable Bowel Syndrome

Australia
GlaxoSmithKline

Completed

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
GlaxoSmithKline

Completed

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States, Australia
The University of Queensland
Princess Alexandra Hospital, Brisbane, Australia; Macquarie University, Australia

Recruiting

A Practice Change for Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms

Gastrointestinal Diseases | Irritable Bowel Syndrome

Australia
Medical University of Vienna

Completed

Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease

IBD | IBS

Austria
Medical University of Vienna

Completed

Resilience in Irritable Bowel Syndrome and Gut-focused Hypnotherapy

Irritable Bowel Syndrome

Austria
GlaxoSmithKline

Completed

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Colon

United States, Spain, South Africa, Sweden, Australia, Canada, Germany, United Kingdom, France, Netherlands
Scigenia GmbH

Completed

Panaceo "MED" for IBS (Irritable Bowel Syndrome) (PCeo-17)

Irritable Bowel Syndrome | Microbial Colonization | Intestinal Disease

Austria
Medical University of Vienna

Completed

Bridging Intestinal Failure With Teduglutide - a Case Report

Short Bowel Syndrome

Austria
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Taiwan, Australia, Canada, Hungary, Spain, Finland, United Kingdom, Hong Kong, Sweden, Austria, Denmark, Poland, Netherlands, New Zealand, Ireland, Switzerland
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Australia, Canada, Hungary, Netherlands, Spain, Sweden, France, New Zealand, Norway, South Africa, Switzerland
Odyssey Therapeutics

Recruiting

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Spondyloarthritis | Blau Syndrome

Australia
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Constipation | Bowel Dysfunction

United States, Netherlands, Spain, Taiwan, Peru, Philippines, France, United Kingdom, Canada, Czechia, Finland, Korea, Republic of, Hong Kong, Pakistan, Thailand, Italy, Argentina, Poland, Hungary, Germany, Russian Federation, South... and more
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Germany, Estonia, Finland, United Kingdom, Canada, Austria, Denmark, Poland, Ireland
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials on Constipation Predominant Irritable Bowel Syndrome in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations